Resveratrol has anti-thyroid effects both in vitro and in vivo

Food and Chemical Toxicology

Volumn 107, Issue , 2017, Pages 237-247

  Giuliani, Cesidio ^a   Iezzi, Manuela ^a   Ciolli, Laura ^a   Hysi, Alba ^a   Bucci, Ines ^a   Di Santo, Serena ^a   Rossi, Cosmo ^a   Zucchelli, Mirco ^a   Napolitano, Giorgio ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Endocrine disruptor; FRTL 5; Goiter; Resveratrol; Thyroid

Indexed keywords

ANTITHYROID AGENT; ENDOCRINE DISRUPTOR; RESVERATROL; THYROGLOBULIN; THYROID HORMONE; THYROID PEROXIDASE; THYROTROPIN; THYROTROPIN RECEPTOR; TRANSCRIPTION FACTOR PAX8; IODIDE PEROXIDASE; STILBENE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; RAT; SPRAGUE DAWLEY RAT; THYROID GLAND; THYROID WEIGHT; ANALYSIS; ANIMAL; CELL LINE; CELL PROLIFERATION; DIETARY SUPPLEMENT; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; METABOLISM;

ANIMALS; ANTITHYROID AGENTS; CELL LINE; CELL PROLIFERATION; DIETARY SUPPLEMENTS; IODIDE PEROXIDASE; RATS; RATS, SPRAGUE-DAWLEY; STILBENES; THYROGLOBULIN; THYROID GLAND; THYROID HORMONES;

EID: 85022078870     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2017.06.044     Document Type: Article

References (57)

1. Amakura, Y., Tsutsumi, T., Sasaki, K., Nakamura, M., Yoshida, T., Maitani, T., Influence of food polyphenols on aryl hydrocarbon receptor-signaling pathway estimated by in vitro bioassay. Phytochemistry 69 (2008), 3117–3130.
2. Ambesi Impiombato, F.S., Fast-growing Thyroid Cell Strain. FRTL-5. US Patent 4,608,341, 1986, Interthyr Research Foundation Inc., MD, USA 26 August 1986.
3. Blanchard, O.L., Smoliga, J.M., Translating dosages from animal models to human clinica trials-revisiting body surface area scaling. FASEB J. 29 (2015), 1629–1634.
4. Boocock, D.J., Faust, G.E., Patel, K.R., Schinas, A.M., Brown, V.A., Ducharme, M.P., Booth, T.D., Crowell, J.A., Perloff, M., Gescher, A.J., Steward, W.P., Brenner, D.E., Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol. Biomarkers Prev. 16 (2007), 1246–1252.
5. Bottner, M., Christoffel, J., Rimoldi, G., Wuttke, W., Effects of long-term treatment with resveratrol and subcutaneous and oral estradiol administration on the pituitary-thyroid-axis. Exp. Clin. Endocrinol. Diabetes 114 (2006), 82–90.
6. Britton, R.G., Kovoor, C., Brown, K., Direct molecular targets of resveratrol: identifying key interactions to unlock complex mechanisms. Ann. N.Y. Acad. Sci. 1348 (2015), 124–133.
7. Calabrese, E.J., Mattson, M.P., Calabrese, V., Resveratrol commonly displays hormesis: occurrence and biomedical significance. Hum. Exp. Toxicol. 29 (2010), 980–1015.
8. Catalgol, B., Batirel, S., Taga, Y., Ozer, N.K., Resveratrol: French paradox revisited. Front. Pharmacol., 3, 2012, 141, 10.3389/fphar.2012.00141.
9. Chachay, V.S., Kirkpatrick, C.M.J., Hickman, I.J., Ferguson, M., Prins, J.B., Martin, J.H., Resveratrol - pills to replace a healthy diet?. Br. J. Clin. Pharmacol. 72 (2011), 27–38.
10. de Souza dos Santos, M.C., Goncalves, C.F.L., Vaisman, M., Ferreira, A.C.F., de Carvalho, D.P., Impact of flavonoids on thyroid function. Food Chem. Toxicol. 49 (2011), 2495–2502.
11. Diaz-Gerevini, G.T., Repossi, G., Dain, A., Tarres, M.C., Das, U.N., Eynard, A.R., Beneficial actions of resveratrol: how and why?. Nutrition 32 (2016), 174–178.
12. Duntas, L.H., Resveratrol and its impact on aging and thyroid function. J. Endocrinol. Invest 34 (2011), 788–792.
13. Fernandez Rodriguez, A., Galera Davidson, H., Salguero Villadiego, M., Moreno Fernandez, A., Martin Lacave, I., Fernandez Sanz, J., Induction of thyroid proliferative changes in rats treated with antithyroid compound. Anat. Histol. Embryol. 20 (1991), 289–298.
14. Ge, J.F., Xu, Y.Y., Qin, G., Cheng, J.Q., Chen, F.H., Resveratrol ameliorates the anxiety- and depression-like behavior of subclinical hypothyroidism rat: possible involvement of the HPT axis, HPA axis, and Wnt/β-catenin pathway. Front. Endocrinol., 7, 2016, 44, 10.3389/fendo.2016.00044.
15. Giuliani, C., Saji, M., Bucci, I., Fiore, G., Liberatore, M., Singer, D.S., Monaco, F., Kohn, L.D., Napolitano, G., Transcriptional regulation of major histocompatibility complex class I gene by insulin and IGF-I in FRTL-5 thyroid cells. J. Endocrinol. 189 (2006), 605–615.
16. Giuliani, C., Noguchi, Y., Harii, N., Napolitano, G., Tatone, D., Bucci, I., Piantelli, M., Monaco, F., Kohn, L.D., The flavonoid quercetin regulates growth and gene expression in rat FRTL-5 thyroid cells. Endocrinology 149 (2008), 84–92.
17. Giuliani, C., Bucci, I., Montani, V., Singer, D.S., Monaco, F., Kohn, L.D., Napolitano, G., Regulation of major histocompatibility complex gene expression in thyroid epithelial cells by methimazole and phenylmethimazole. J. Endocrinol. 204 (2010), 57–66.
18. Giuliani, C., Bucci, I., Di Santo, S., Rossi, C., Grassadonia, A., Piantelli, M., Monaco, F., Napolitano, G., The flavonoid quercetin inhibits thyroid-restricted genes expression and thyroid function. Food Chem. Toxicol. 66 (2014), 23–29.
19. Giuliani, C., Bucci, I., Di Santo, S., Rossi, C., Grassadonia, A., Mariotti, M., Piantelli, M., Monaco, F., Napolitano, G., Resveratrol inhibits sodium/iodide symporter gene expression and function in rat thyroid cells. PLoS One, 9(9), 2014, e107936, 10.1371/journal.pone.0107936.
20. Han, G., Xia, J., Gao, J., Inagaki, Y., Tang, W., Kokudo, N., Anti-tumor effects and cellular mechanisms of resveratrol. Drug Discov. Ther. 9 (2015), 1–12.
21. Hardin, H., Yu, X.-M., Harrison, A.D., Larrain, C., Zhang, R., Chen, J., Chen, H., Lloyd, R.V., Generation of novel thyroid cancer stem-like cell clones: effects of resveratrol and valproic acid. Am. J. Pathol. 186 (2016), 1662–1673.
22. Heebøll, S., Kreuzfeldt, M., Hamilton-Dutoit, S., Kjaer Poulsen, M., Stødkilde-Jørgensen, H., Møller, H.J., Jessen, N., Thorsen, K., Kristina Hellberg, Y., Bønløkke Pedersen, S., Grønbæk, H., Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease. Scand. J. Gastroenterol. 51 (2016), 456–464.
23. Hosseinimehr, S.J., Hosseini, S.A.H., Resveratrol sensitizes selectively thyroid cancer cell to 131-Iodine toxicity. J. Toxicol., 2014, 2014, 839597, 10.1155/2014/839597 Epub 2014 Sep 3.
24. Howells, L.M., Berry, D.P., Elliot, P.J., Jacobson, E., Hegarty, B., Brown, K., Steward, W.P., Gescher, A.J., Phase I randomized, double-blind study of micronized resveratrol (SRT501) in patients with hepatic metastases – safety, pharmacokinetics, and pharmacodynamics. Cancer Prev. Res. 4 (2011), 1419–1425.
25. Kang, H.J., Youn, Y.K., Hong, M.K., Kim, L.S., Antiproliferation and redifferentiation in thyroid cancer cell lines by polyphenol phytochemicals. J. Korean Med. Sci. 26 (2011), 893–899.
26. Kimura, S., Thyroid-specific transcription factors and their roles in thyroid cancer. J. Thyroid. Res., 2011, 2011, 710213, 10.4061/2011/710213.
27. Knobel, M., Etiopathology, clinical features, and treatment of diffuse and multinodular nontoxic goiters. J. Endocrinol. Invest 39 (2016), 357–373.
28. Kogai, T., Ohashi, E., Jacobs, M.S., Sajid-Crockett, S., Fisher, M.L., Kanamoto, Y., Brent, G.A., Retinoic acid stimulation of the sodium/iodide symporter in MCF-7 breast cancer cells is mediated by the insulin growth factor-I/phosphatidylinositol 3-kinase and p38 mitogen-activated protein kinase signaling pathways. J. Clin. Endocrinol. Metab. 93 (2008), 1884–1892.
29. Kohn, L.D., Valente, W.A., FRTL-5 manual: a current guide. Ambesi Impiombato, F.S., Perrild, H., (eds.) FRTL-5 Today, 1989, Excerpta Medica, Amsterdam, The Netherlands, 243–273.
30. Kohn, L.D., Shimura, H., Shimura, Y., Hidaki, A., Giuliani, C., Napolitano, G., Ohmori, M., Laglia, G., Saji, M., The thyrotropin receptor. Vitam. Horm. 50 (1995), 287–384.
31. Krohn, K., Führer, D., Bayer, Y., Eszlinger, M., Brauer, V., Neumann, S., Paschke, R., Molecular pathogenesis of euthyroid and toxic multinodular goiter. Endocr. Rev. 26 (2005), 504–524.
32. Kumar, A., Chauhan, S., How much successful are the medicinal chemists in modulation of SIRT1: a critical review. Eur. J. Med. Chem. 119 (2016), 45–69.
33. Kweon, K.H., Lee, C.R., Jung, S.J., Ban, E.J., Kang, S.-W., Jeong, J.J., Nam, K.-H., Jo, Y.S., Lee, J., Chung, W.Y., Sirt1 induction confers resistance to etoposide-induced genotoxic apoptosis in thyroid cancers. Int. J. Oncol. 45 (2014), 2065–2075.
34. Larrosa, M., Azorin-Ortuno, M., Yanez-Gascon, M.J., Garcia-Conesa, M.T., Tomas-Barberan, F., Espin, J.C., Lack of effect of oral administration of resveratrol in LPS-induced systemic inflammation. Eur. J. Nutr. 50 (2011), 673–680.
35. Lin, R., Hogen, V., Cannon, S., Marion, K.M., Fenton, M.S., Hershman, J.M., Stability of recombinant human thyrotropin potency based on bioassay in FRTL-5 cells. Thyroid 20 (2010), 1139–1143.
36. Marier, J.-F., Vachon, P., Gritsas, A., Zhang, J., Moreau, J.-P., Ducharme, M.P., Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J. Pharmacol. Exp. Ther. 302 (2002), 369–373.
37. Meng, X., Maliakal, P., Lu, H., Lee, M.-J., Yang, C.S., Urinary and plasma levels of resveratrol and quercetin in humans, mice, and rats after ingestion of pure compounds and grape juice. J. Agric. Food Chem. 52 (2004), 935–942.
38. Mennen, L.I., Walker, R., Bennetau-Pelissero, C., Scalbert, A., Risks and safety of polyphenol consumption. Am. J. Clin. Nutr. 81:Suppl. l (2005), 326S–329S.
39. Novelle, M.G., Wahl, D., Dieguez, C., Bernier, M., de Cabo, R., Resveratrol supplementation: where are we now and where should we go?. Ageing Res. Rev. 21 (2015), 1–15.
40. Park, E.J., Pezzuto, J.M., The pharmacology of resveratrol in animals and humans. Biochim. Biophys. Acta 1852 (2015), 1071–1113.
41. Pocar, P., Klonisch, T., Brandsch, C., Eder, K., Fröhlich, C., Hoang-Vu, C., Hombach-Klonisch, S., AhR-agonist-induced transcriptional changes of genes involved in thyroid function in primary porcine thyrocytes. Toxicol. Sci. 89 (2006), 408–414.
42. Reagan-Shaw, S., Nihal, M., Ahmad, N., Dose translation from animal to human studies revisited. FASEB J. 22 (2007), 659–661.
43. Schmutzler, C., Winzer, R., Meissner Weigl, J., Kohrle, J., Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells. Biochem. Biophys. Res. Commun. 240 (1997), 832–838.
44. Sebastià, N., Montoro, A., Hervas, D., Pantelias, G., Hatzi, V.I., Soriano, J.M., Villaescusa, J.I., Terzoudi, G.I., Curcumin and trans-resveratrol exert cell cycle-dependent radioprotective or radiosensitizing effects as elucidated by the PCC and G2-assay. Mutat. Res. 766–767 (2014), 49–55.
45. Singh, S.U.N., Casper, R.F., Fritz, P.C., Sukhu, B., Ganss, B., Girard, B. Jr., Savouret, J.F., Tenenbaum, H.C., Inhibition of dioxin effects on bone formation in vitro by a newly described aryl hydrocarbon receptor antagonist, resveratrol. J. Endocrinol. 167 (2000), 183–195.
46. Smerdely, P., Pitsiavas, V., Boyages, S., Methimazole inhibits FRTL5 thyroid cell proliferation by inducing S-phase arrest of the cell cycle. Endocrinology 133 (1993), 2403–2406.
47. Tani, Y., Maronpot, R.R., Foley, J.F., Haseman, J.K., Walker, N.J., Nyska, A., Follicular epithelial cell hypertrophy induced by chronic oral administration of 2,3,7,8-tetrachlorodibenzo-p-dioxin in female Harlan Sprague-Dawley rats. Toxicol. Pathol. 32 (2004), 41–49.
48. Thazhath, S.S., Wu, T., Bound, M.J., Checklin, H.L., Standfield, S., Jones, K.L., Horowitz, M., Rayner, C.K., Administration of resveratrol for 5 wk has no effect on glucagon-like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial. Am. J. Clin. Nutr. 103 (2016), 66–70.
49. Tomé-Carneiro, J., Larrosa, M., González-Sarrias, A., Tomas-Barberán, F.A., Garcia-Conesa, M.T., Espin, J.C., Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence. Curr. Pharm. Des. 19 (2013), 6064–6093.
50. Tsujio, M., Watahiki, Y., Yoshioka, K., Mutoh, K., Morphology of thyroid follicular cells of methimazole-treated rats. Anat. Histol. Embryol. 36 (2007), 290–294.
51. Turner, R.S., Thomas, R.G., Craft, S., van Dyck, C.H., Mintzer, J., Reynolds, B.A., Brewer, J.B., Rissman, R.A., Raman, R., Aisen, P.S., A randomised, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology 85 (2015), 1383–1391.
52. Vang, O., What is new for reveratrol? Is a new set of recommendations necessary?. Ann. N.Y. Acad. Sci. 1290 (2013), 1–11.
53. Velicky, J., Titlbach, M., Lojda, Z., Jelinek, F., Vobecky, M., Raska, I., Expression of the proliferating cell nuclear antigen (PCNA) in the rat thyroid gland after exposure to bromide. Acta histochem. 99 (1997), 391–399.
54. Xu, B., Yang, H., Sun, M., Chen, H., Jiang, L., Zheng, X., Ding, G., Liu, Y., Sheng, Y., Cui, D., Duan, Y., 2,3’,4,4’,5-Pentachlorobiphenyl induces inflammatory responses in the thyroid through JNK and aryl hydrocarbon receptor-mediated pathway. Toxicol. Sci. 149 (2016), 300–311.
55. Yoon, D.S., Choi, Y., Choi, S.M., Park, K.H., Lee, J.W., Different effects of resveratrol on early and late passage mesenchymal stem cells through β-catenin regulation. Biochem. Byophys. Res. Commun. 467 (2015), 1026–1032.
56. Yu, X.M., Jaskula Sztul, R., Ahmed, K., Harrison, A.D., Kunnimalaiyaan, M., Chen, H., Resveratrol induces differentiation markers expression in anaplastic thyroid carcinoma via activation of Notch 1 signaling and suppresses cell growth. Mol. Cancer. Ther. 12 (2013), 1276–1287.
57. Zhao, F., Wang, J., Fang, Y., Ding, J., Yang, H., Li, L., Xi, Z., Qiao, H., Effects of tris(1,3-dichloro-2-propyl)phosphate on pathomorphology and gene/protein expression related to thyroid disruption in rats. Toxicol. Res. 5 (2016), 921–930.